Literature DB >> 14557368

Aldosterone regulates vascular reactivity: short-term effects mediated by phosphatidylinositol 3-kinase-dependent nitric oxide synthase activation.

Selina L Liu1, Saskia Schmuck, Jozef Z Chorazcyzewski, Robert Gros, Ross D Feldman.   

Abstract

BACKGROUND: There is increasing evidence for rapid nongenomic effects of aldosterone. Therefore, we studied the immediate effects of aldosterone on vascular reactivity in rat aortic ring segments and on endothelial and vascular smooth muscle cellular responses. METHODS AND
RESULTS: In endothelium-intact ring segments, aldosterone attenuated phenylephrine-mediated constriction (maximal reduction, 25+/-4% below control phenylephrine-mediated constriction). In contrast, in endothelium-denuded vessels, aldosterone mediated a monophasic dose-dependent enhancement of vasoconstrictor response. In endothelial cells, aldosterone caused a phosphatidylinositol 3-kinase (PI3K)-dependent increase in nitric oxide synthase activity as well as PI3K-dependent activation of extracellular signal-regulated kinase 1/2 and p70 S6 kinase.
CONCLUSIONS: Overall, these data support a novel effect of aldosterone on vascular endothelial and smooth muscle cell function. These rapid effects of aldosterone might be important in both the short- and long-term regulation of peripheral vascular resistance. Furthermore, in the setting of endothelial dysfunction, alterations in aldosterone's short-term vascular responses might contribute to its pathophysiological effects in cardiovascular disease.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14557368     DOI: 10.1161/01.CIR.0000093188.53554.44

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  32 in total

1.  Mineralocorticoid-receptor blockade in hypertensive patients during angiotensin-converting enzyme inhibition: effects on left ventricular mass.

Authors:  Robert M Carey; Alexander G Logan
Journal:  Curr Hypertens Rep       Date:  2004-04       Impact factor: 5.369

2.  Low doses of fludrocortisone and hydrocortisone, alone or in combination, on vascular responsiveness to phenylephrine in healthy volunteers.

Authors:  Bruno Laviolle; Erwan Donal; Pascale Le Maguet; Fabrice Lainé; Eric Bellissant
Journal:  Br J Clin Pharmacol       Date:  2013-02       Impact factor: 4.335

3.  New roles of aldosterone and mineralocorticoid receptors in cardiovascular disease: translational and sex-specific effects.

Authors:  Ana Paula Davel; Iris Z Jaffe; Rita C Tostes; Frederic Jaisser; Eric J Belin de Chantemèle
Journal:  Am J Physiol Heart Circ Physiol       Date:  2018-06-29       Impact factor: 4.733

Review 4.  Mineralocorticoid receptors in vascular function and disease.

Authors:  Amy McCurley; Iris Z Jaffe
Journal:  Mol Cell Endocrinol       Date:  2011-06-24       Impact factor: 4.102

Review 5.  The multifaceted mineralocorticoid receptor.

Authors:  Elise Gomez-Sanchez; Celso E Gomez-Sanchez
Journal:  Compr Physiol       Date:  2014-07       Impact factor: 9.090

Review 6.  Aldosterone breakthrough during RAS blockade: a role for endothelins and their antagonists?

Authors:  Gian Paolo Rossi
Journal:  Curr Hypertens Rep       Date:  2006-06       Impact factor: 5.369

7.  Nitric oxide-mediated dilation of arterioles to intraluminal administration of aldosterone.

Authors:  Erwan Heylen; An Huang; Dong Sun; Gabor Kaley
Journal:  J Cardiovasc Pharmacol       Date:  2009-12       Impact factor: 3.105

Review 8.  Genomic and rapid effects of aldosterone: what we know and do not know thus far.

Authors:  Milla Marques Hermidorff; Leonardo Vinícius Monteiro de Assis; Mauro César Isoldi
Journal:  Heart Fail Rev       Date:  2017-01       Impact factor: 4.214

Review 9.  Skeletal muscle insulin resistance in endocrine disease.

Authors:  Melpomeni Peppa; Chrysi Koliaki; Panagiotis Nikolopoulos; Sotirios A Raptis
Journal:  J Biomed Biotechnol       Date:  2010-03-15

Review 10.  Direct contribution of vascular mineralocorticoid receptors to blood pressure regulation.

Authors:  Kathleen V Barrett; Amy T McCurley; Iris Z Jaffe
Journal:  Clin Exp Pharmacol Physiol       Date:  2013-12       Impact factor: 2.557

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.